Sponsored by and content developed in conjunction with Ortho Women's Health and Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
May 1, 2010|OBG Management
Author and Disclosure Information
Andrew M. Kaunitz, MD Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida
Catherine L. Dean, MD, MPH Clinical Assistant Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine, Managing Partner, Women’s HealthPartners, Inc., St. Louis, Missouri
Dr Kaunitz reports the following: Consultant and/or speakers bureau, and research support:Bayer HealthCare Pharmaceuticals, Merck & Co., Inc., Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. Dr Kaunitz has been compensated for his work on this publication.
Dr Dean reports the following: Speakers bureau: Bayer HealthCare Pharmaceuticals, and Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Dr Dean has been compensated for her work on this publication.
Highlights from a randomized clinical trial comparing a 21-day and a 24-day oral contraceptive regimen
Unscheduled bleeding (ie, spotting/breakthrough bleeding) and early, late, or absent withdrawal bleeding are common reasons cited by women for discontinuing use of oral contraceptives (OCs).3-5 A European survey of nearly 7000 current or past users of OCs found that women who experienced side effects such as unscheduled bleeding in the first 3 months of use were nearly twice as likely to discontinue use as those who reported no cycle control problems during this time.4
